Altre lingue Biosergen AB

Azioni

BIOSGN

SE0016013460

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 16:50:19 24/04/2024			Variaz. 5gg	Var. 1 gen.
0,349 ^SEK	-9,82%		-22,44%	-60,34%

09/04	Biosergen emetterà nuove unità come compenso nell'ambito dell'emissione di diritti	MT
27/03	Biosergen raccoglie 26,4 milioni di corone svedesi attraverso un'emissione di diritti	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Conversion of paid subscribed units and first day of trading with warrants of series TO3	16/04
Biosergen to Issue New Units as Compensation Under Rights Issue	09/04
Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue	09/04
Biosergen Raises SEK26.4 Million via Rights Issue	27/03
Biosergen announces the outcome in the rights issue	26/03
BioStock Investor Pitch: Biosergen	18/03
Members of the board of directors and management subscribe in ongoing rights issue	15/03
Research update Biosergen: Rights issue to fund crucial step for lead project	13/03
BioStock: Rights issue to give Biosergen first in-human efficacy data	12/03
BioStock: Biosergen attacks invisible threat of fungal infections	08/03
Carlsquare Equity Research interview with Biosergen	07/03
Biosergen CEO to BioStock: "Positive data give us a strong value proposition"	07/03
Biosergen publishes prospectus due to rights issue of units	05/03
Bulletin from the extraordinary general meeting in Biosergen AB (publ)	01/03
Biosergen publishes interim report for fourth quarter 2023	29/02
Biosergen AB Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Norway's Biosergen Secures Indian Regulatory Approval for Clinical Trial of Fungal Infections Therapy	12/02
Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.	12/02
Biosergen AB Receives Regulatory Approval to Test Lead Candidate Bsg005 in Patients with Invasive Fungal Infection	12/02
Mrkt BUZZ, Biosergen: Rights issue to fund the next clinical step	02/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Biosergen AB

Azioni

BIOSGN

SE0016013460

Altre lingue

Filtri